News
Freshfields Advises Roivant on Sale of Telavant to Roche for $7.1 billion in Cash and a Near-term Milestone Payment of $150 Million in Cash
Freshfields is advising Roivant Sciences Ltd. (Nasdaq: ROIV) on the sale of Telavant, a Roivant company owned by Roivant and Pfizer, to Roche for $7.1 billion in cash and a near-term milestone payment of $150 million in cash. More details on the transaction can be found here.
The Freshfields team is led by M&A partners Damien Zoubek and Jenny Hochenberg, senior associates Tomas Rua and Arash Ardalan, and associates Joyce Yeo, Connor Smith and Clara Barnosky. Partner Adam Golden, counsel Jeff Jay and associates Sora Park and Joshua Samuel advised on life sciences matters; partner Lori Goodman, senior associate Andrew Herman and associate Lina Zhu advised on executive compensation and employee benefits matters; partners Joe Soltis and Paul Davison and associates Emily Szasz, Brendan Counihan and Hannah Golden advised on tax matters; and partners Jamillia Ferris, Meghan Rissmiller and Jenny Leahy advised on antitrust matters.
About Freshfields Bruckhaus Deringer LLP
Freshfields Bruckhaus Deringer is a global law firm with a long-standing track record of successfully supporting the world's leading national and multinational corporations, financial institutions and governments on groundbreaking and business-critical mandates. Our 2,800-plus lawyers deliver results worldwide through our own offices and alongside leading local firms. Our commitment, local and multinational expertise, and business know-how means our clients rely on us when it matters most.
Freshfields is ranked by Chambers Global in Band 1 across the six areas of antitrust, corporate/M&A, litigation, international arbitration, tax, and public international law. For more information visit Freshfields.us.
